Eli Lilly and Company (LLY) — Q2 2026 Earnings Preview

Ticker: LLY | Earnings Date: August 5, 2026 (Pre-Market) | Reporting Period: Q2 2026 | Prepared: August 4, 2026

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus is a manageable bar after Q1's massive upside surprise — but the single biggest swing factor is Foundayo (orforglipron) early launch traction and whether management raises full-year guidance again.

Heading into Q2 2026, the bar for LLY looks beatable but not trivially so: consensus revenue of ~$20.6B implies roughly 32% YoY growth, a step-up from Q1's already-elevated base, yet management's raised full-year guidance ($82–$85B) embeds continued incretin momentum that the street has largely followed. Mounjaro and Zepbound remain the primary revenue engines, with consensus expecting ~$8.9B and ~$4.7B respectively — both achievable given Q1's $8.7B/$4.2B actuals and the sequential volume ramp underway. Management's tone since the April 30 print has been unambiguously confident: the ADA investor event on June 6 showcased bariatric-surgery-level retatrutide data (28.3% weight loss at 12mg), Foundayo's DTC advertising launched June 8 on NBA broadcasts, and CVS Caremark completed full PBM coverage of Lilly's obesity portfolio by June 1 — all tailwinds that were not fully in the Q1 guide. Estimate revisions have drifted modestly higher since the Q1 print, with FY 2026 consensus EPS moving from ~$36.8 to ~$34.8 (reflecting some conservatism on Foundayo ramp timing), while revenue estimates have been broadly stable. The stock has rallied ~19% since the Q1 earnings date (April 30), outperforming XBI (+16%) and SPY (+7%), suggesting the market has partially priced in continued execution — but at ~33x forward earnings, the multiple still requires near-flawless delivery. The key wildcard is Foundayo's early commercial metrics: management guided to a back-half acceleration driven by full DTC activation and Medicare Part D access beginning July 1; any quantification of prescriber counts, new-to-class patient share, or LillyDirect volume could be the decisive beat/miss signal for the quarter.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a high but achievable bar on revenue (~$20.6B, +32% YoY) given Q1's massive beat; Mounjaro volume is the bigger swing factor, while Foundayo's ramp trajectory is the incremental read-through that could move the stock most on print day.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus and actuals data. All consensus figures as of August 4, 2026. Q2 2026 actuals not yet reported.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

KPI 1: Total Revenue | KPI 2: EPS — Diluted Operating

Pattern: LLY has beaten consensus on both revenue and operating EPS in every one of the last four reported quarters, with revenue surprise averaging ~9% and EPS surprise averaging ~17% — a consistent pattern of management setting a beatable bar and then delivering well above it on incretin volume strength.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year guidance was raised by $2B on revenue and $2 on EPS at the Q1 print (April 30); no further formal revision since, but management tone has grown more confident through the ADA investor event and CVS Caremark coverage milestone.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Revenue estimates for Q2 2026 and FY 2026 have been broadly stable since the Q1 print, tracking close to guidance; EPS estimates have drifted modestly lower (FY consensus ~$34.8 vs. guidance midpoint $36.25), reflecting Foundayo launch investment and R&D ramp — creating a potential cushion if incretin volumes surprise again.

Source: Visible Alpha consensus and actuals data. Note: The large Q2 2026 EPS estimate decline from the May 5 baseline reflects a data artifact — the May 5 as-of snapshot captured an elevated post-Q1 beat consensus that was subsequently normalized. FY 2026 EPS consensus of ~$34.8 sits ~3.9% below the guidance midpoint of $36.25, creating a potential cushion if incretin volumes continue to outperform.

5. Stock Performance

Key Takeaway: LLY has rallied ~19% since the Q1 earnings date (April 30), outperforming both XBI (+16%) and SPY (+7%) — driven primarily by retatrutide TRIUMPH-1 data (28.3% weight loss), Foundayo DTC launch, and full PBM coverage completion; the stock is entering Q2 earnings near its post-Q1 highs, suggesting the market has partially priced in continued execution.

LLY vs. XBI (Biotech ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (April 30, 2026). Source: Yahoo Finance.

Key Events Since Q1 Earnings (April 30, 2026):

• May 21: TRIUMPH-1 top-line data released — retatrutide showed 28.3% weight loss at 12mg (80 weeks), approaching bariatric surgery levels. Stock surged to ~$1,065 (+14% from earnings base).
• May 28: CVS Caremark announced Foundayo coverage effective June 1 and Zepbound coverage resumption by October 1, completing full PBM access across all three major PBMs. Stock hit ~$1,127.
• June 6–8: ADA investor event showcased detailed TRIUMPH-1 and TRANSCEND-T2D-1 data; Foundayo DTC advertising launched June 8 (NBA broadcast). Stock reached ~$1,149 (peak since Q1 earnings).
• June 26: Stock surged to ~$1,208 on continued incretin momentum and Medicare Part D bridge program confirmation through December 2027.
• July 7–9: Stock reached cycle high of ~$1,236 before pulling back ~10% into earnings, with some profit-taking ahead of the print.
• August 4 (today): LLY closed at $1,115.68, with post-market at $1,129.99 (+1.3%), suggesting some pre-earnings positioning.

Sector ETF used: XBI (SPDR S&P Biotech ETF) — appropriate for LLY's large-cap biopharma sub-sector given its GLP-1/obesity franchise focus and pipeline-driven valuation. LLY's outperformance vs. XBI reflects company-specific catalysts (retatrutide data, Foundayo launch) rather than broad biotech sentiment.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the TRIUMPH-1 retatrutide data (28.3% weight loss) — which materially expands LLY's addressable market and competitive moat — followed closely by Foundayo achieving full PBM coverage and DTC activation, both of which set up a stronger Q3/Q4 ramp than the street had modeled.

• May 21, 2026 — TRIUMPH-1 Retatrutide Data Released: Phase 3 obesity data showed 28.3% weight loss at 12mg (80 weeks), extending to 30.3% in the extension cohort — approaching bariatric surgery levels. The 4mg dose delivered 19% weight loss with a single titration step and a discontinuation rate due to adverse events below placebo.
• Implication: Retatrutide NDA filing on track for H2 2026; data materially broadens the addressable patient population and reinforces LLY's multi-product obesity franchise moat.
• May 28, 2026 — CVS Caremark Completes Full PBM Coverage: CVS Caremark announced Foundayo coverage effective June 1 and Zepbound coverage resumption by October 1, completing access across all three of the nation's largest PBMs (Express Scripts, OptumRx, CVS Caremark).
• Implication: Removes the primary commercial access overhang for Foundayo; accelerates the commercial ramp into Q3 2026.
• June 6, 2026 — ADA Cardiometabolic Health Portfolio Investor Event: Management presented detailed TRIUMPH-1 and TRANSCEND-T2D-1 data; confirmed Foundayo T2D FDA submission on track for Q2 2026; highlighted 'strong use' in lower-BMI patients and 'more and more people starting on this medicine every day.' Retatrutide submission confirmed for H2 2026.
• June 8, 2026 — Foundayo DTC Advertising Launched: Full-scale direct-to-consumer TV advertising for Foundayo launched on NBA broadcasts, marking the activation of the third key commercial lever (after HCP promotion and PBM access).
• Implication: DTC activation is the primary driver of the expected back-half Foundayo ramp; early consumer awareness metrics will be a key Q2 call focus.
• July 1, 2026 — Medicare Part D GLP-1 Bridge Program Begins: The government's $50/month out-of-pocket cap bridge program for Medicare beneficiaries began, covering both Zepbound and Foundayo through December 2027.
• Implication: Opens a new patient segment (seniors) that was previously largely excluded; management expects population-level health data from this cohort to support permanent Part D coverage in 2028.
• July 8, 2026 — Analyst Price Target Upgrades: Morgan Stanley raised PT to $1,347 (Overweight); Truist raised PT to $1,370 (Buy); Guggenheim raised PT to $1,273 (Buy) — all citing retatrutide data and Foundayo launch momentum. Consensus rating: Moderate Buy, average PT ~$1,284.
• July 22, 2026 — Q2 2026 Earnings Date Confirmed: Lilly confirmed August 5, 2026 pre-market earnings release with a 10 a.m. ET conference call.
• Ongoing — Foundayo International Regulatory Reviews: Regulatory reviews ongoing in 45+ countries for obesity and T2D indications; UAE approval received within 24 hours of U.S. approval. Management expects Foundayo to be first-to-market oral GLP-1 in many international markets, with launches expected as LLY exits 2026 into 2027.
• Ongoing — Lilly Employer Connect Platform: Employer Connect program offering transparent pricing and flexible employer-employee cost-sharing is gaining traction; management noted positive conversations but expects gradual impact in H2 2026 and incremental opt-ins for 2027.

7. Peer Commentaries — Read-Through for LLY Q2 2026

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for LLY — NVO's Wegovy pill data confirms the oral GLP-1 market is expanding (not cannibalizing injectables), AMGN's maritime Phase 3 progress validates the obesity market's long-term scale, and VKTX's commercial ecosystem commentary (50% cash pay, Medicare access July 1, direct-to-employer growth) directly supports LLY's Foundayo and Zepbound volume thesis. The most important read-through is NVO's confirmation that oral GLP-1 launches attract ~80% new-to-class patients — a direct positive signal for Foundayo's market expansion narrative.

Novo Nordisk (NVO) — Q1 2026 Earnings Call (May 6, 2026) & ADA R&D Day (June 7, 2026)

Relevance to LLY Q2 2026: HIGH. NVO is LLY's primary competitor in both injectable and oral GLP-1 markets. NVO's commentary on the Wegovy pill launch provides the most direct read-through for Foundayo's commercial trajectory.

• Oral GLP-1 market expansion confirmed: NVO reported the Wegovy pill reached 3 million prescriptions by week 22 (as of early June 2026), with ~80% of users being GLP-1 treatment-naive patients. This directly validates LLY's thesis that Foundayo will expand the market rather than cannibalize injectables — a key investor concern heading into Q2.
• Oral GLP-1 not cannibalizing injectables: NVO explicitly noted 'limited cannibalization from injectable Wegovy' and that patients are 'coming to Wegovy pill from competitor products.' This is a direct positive read-through for Zepbound's volume trajectory in Q2.
• Intensifying competition acknowledged: NVO's Q2 2026 outlook explicitly cited 'intensifying competition' in U.S. operations, referencing Foundayo's launch. However, NVO's own data showed the Wegovy pill accelerating despite Foundayo's arrival — suggesting the market is large enough for both.
• Efficacy comparison framing: NVO management cited an indirect treatment comparison showing 'better efficacy with Wegovy pill than the competitor [Foundayo] as well as a lower likelihood of discontinuation due to adverse events.' This sets up a potential debate on Q2 call about Foundayo's competitive positioning vs. Wegovy pill.
• Retatrutide comparison (ADA R&D Day): NVO management disputed the retatrutide T2D data, arguing placebo-corrected A1C reduction was only ~1.1pp vs. CagriSema's ~1.6–1.8pp. This framing will likely be addressed on LLY's Q2 call given the TRIUMPH-1 data released in May.
• Pricing trajectory: NVO confirmed 'further lower realized prices linked to investments in market access amplified by the Most-Favored-Nations agreement' — consistent with LLY's own low-to-mid teens price headwind guidance for FY 2026.

Viking Therapeutics (VKTX) — Q2 2026 Earnings Call (July 29, 2026) & Jefferies Conference (June 4, 2026)

Relevance to LLY Q2 2026: MEDIUM-HIGH. VKTX is a smaller GLP-1/GIP competitor in Phase 3, but its commercial ecosystem commentary provides the most granular read-through on market access dynamics, cash pay trends, and Medicare coverage that directly affect LLY's Foundayo and Zepbound volumes.

• Cash pay segment growing: VKTX management noted 'some of the larger companies have stated recently that 50% of their business is cash pay' and this segment 'is continuing to grow.' This directly validates LLY's Q1 commentary that ~45% of Zepbound prescriptions and ~55% of new prescriptions are self-pay.
• Medicare access (July 1) is a real catalyst: VKTX management highlighted 'Medicare is going to be covering these drugs as of July 1' as a significant new channel, and expressed confidence it 'will not be a duopoly' — suggesting the government will favor competition. This is a direct positive for LLY's Foundayo and Zepbound Medicare bridge program.
• Direct-to-employer channel about to accelerate: VKTX management stated the direct-to-employer segment is 'about to grow really a lot in the next 6 months,' with employers 'carving this benefit out and treating it like a gym membership.' This validates LLY's Employer Connect platform strategy and suggests incremental volume in H2 2026.
• Oral GLP-1 not cannibalizing injectables: VKTX's CCO noted oral market uptake is 'not cannibalizing the injectable market, hardly at all' and represents 'incremental growth' — a direct positive read-through for Zepbound's Q2 volume trajectory alongside Foundayo's launch.
• DTC channels evolving rapidly: VKTX highlighted that DTC companies 'do direct-to-consumer marketing better than big pharma does' and are not interested in exclusive deals — consistent with LLY's LillyDirect strategy and the ~45% of early Foundayo volume flowing through LillyDirect.
• Obesity as chronic disease requiring chronic treatment: VKTX management framed obesity as 'a chronic disease that requires chronic treatment' and emphasized that 'improved adherence to therapy increases the probability of realizing the long-term benefits of weight loss' — supporting LLY's persistency narrative for Mounjaro and Zepbound.

Amgen (AMGN) — Q2 2026 Earnings Call (August 4, 2026) & Jefferies Conference (June 4, 2026)

Relevance to LLY Q2 2026: MEDIUM. AMGN's maritime (monthly GLP-1 antibody) is in Phase 3 and not yet a commercial competitor, but AMGN's commentary on market size, pricing dynamics, and the 'next chapter' of obesity treatment provides useful context for LLY's long-term positioning.

• Market penetration remains extremely low: AMGN management noted current GLP-1 usage is 'about 0.2% or less of the addressable population' of over 1 billion people with obesity globally — reinforcing LLY's own framing that ~3% of the global obesity population is currently treated. This validates the long runway for Mounjaro, Zepbound, and Foundayo volume growth.
• Pricing dynamics in line with expectations: AMGN's commercial team noted pricing trends are 'in line with our expectations' and observed a 'unique market dynamic where price reductions are coming with demand lifts overall' — directly consistent with LLY's Q1 commentary that 'pretty much every time we reduce pricing, we see a pretty large expansion.'
• Long-term maintenance is the next frontier: AMGN framed 'the next chapter in obesity treatment' as 'not simply greater weight loss, but achieving long-term persistent benefit' — validating LLY's eloralintide (amylin) and retatrutide positioning as maintenance and combination therapy options.
• Adherence is the key unmet need: AMGN noted 'half the people today of those 2% that have access to these medicines stop taking the medicine before a year is up' — a read-through that supports LLY's investment in LillyDirect, Employer Connect, and the Medicare bridge program as adherence-driving tools.
• Orforglipron geographic variability flagged (Jefferies): An analyst at the Jefferies conference noted 'for orforglipron, the issue of geographic variability came up pretty prominently because your diet can really impact your nausea rates.' This is a potential Q2 call topic — management may be asked about Foundayo's tolerability profile across different patient populations.
• Manufacturing investment validates market scale: AMGN guided to ~$2.6B in CapEx for 2026 to scale manufacturing for maritime launch — validating the massive manufacturing investments LLY has been making and the long-term market opportunity that justifies them.

AstraZeneca (AZN) — ADA Meet the Management (June 8, 2026) & Q2 2026 Earnings Call (July 27, 2026)

Relevance to LLY Q2 2026: MEDIUM. AZN is a future competitor (oral GLP-1 in Phase 3) but not yet commercial. Its commentary on market segmentation, fixed-dose combinations, and orforglipron's drug interaction profile provides useful context.

• Market segmentation will intensify: AZN management stated 'the market will segment further based on individual needs' and that 'physician patients need more choice' — validating LLY's multi-product obesity strategy (Zepbound, Foundayo, retatrutide, eloralintide) as the right long-term positioning.
• Orforglipron drug interaction profile raised: At the ADA event, analysts noted 'restrictions around simvastatin use, CYP3A4 inhibitors/inducers' for orforglipron, and AZN's own oral GLP-1 (alogliptin) was compared favorably on liver safety. This is a potential Q2 call topic — management may be asked to address Foundayo's drug interaction profile and its impact on the prescribable patient population.
• Oral GLP-1 efficacy bar: AZN's alogliptin showed 11.5% placebo-corrected weight loss at 36 weeks vs. Foundayo's 12.4% in ATTAIN-1 — suggesting the oral GLP-1 efficacy bar is well-established and Foundayo's profile is competitive. AZN's Phase 3 program (BOLD/ILLUMINATE) just initiated, with first data expected H1 2027.
• Fixed-dose combinations as access strategy: AZN CEO Pascal Soriot emphasized FDCs could 'improve compliance' and 'help access because we can price those products at the affordable level' — a strategy LLY may also pursue with Foundayo + other agents, particularly for international markets.
• Less than 5% of eligible patients treated globally: AZN management cited 'less than 5% of eligible patients living with obesity are being treated today all over the world' — consistent with LLY's own ~3% penetration framing and reinforcing the long runway for volume growth.

Pfizer (PFE) — Goldman Sachs Global Healthcare Conference (June 8, 2026) & Q2 2026 Earnings Call (August 4, 2026)

Relevance to LLY Q2 2026: LOW-MEDIUM. PFE's berobenatide (monthly GLP-1) is 2+ years from launch, but CEO Albert Bourla's commentary on market dynamics, pricing, and competitive positioning provides useful context for LLY's long-term moat.

• Monthly dosing as the next competitive frontier: PFE CEO Bourla stated berobenatide will be 'as good in efficacy as the current leading product [tirzepatide]' with 'excellent tolerability and will be monthly,' targeting a commercial launch in 'the beginning of 2028.' This validates LLY's own pursuit of long-acting/monthly incretin formulations as a strategic priority.
• International markets are the 'big surprise': Bourla called international markets 'the big surprise for all of us' — obesity is 'taking off very rapidly' and is 'completely out of pocket,' with 'very little reimbursement.' This is a direct positive read-through for LLY's international Mounjaro franchise (~75% cash pay OUS) and Foundayo's planned international rollout.
• Lilly is 'very entrenched': Bourla explicitly acknowledged competing against 'the very entrenched competitor, which is Lilly' — validating LLY's commercial moat and brand strength in the obesity market heading into Q2.
• Switch studies as the path to market share: PFE's strategy relies on switch studies showing non-inferiority to existing weekly GLP-1s, targeting patients who 'have reached a plateau' or 'dislike constant weekly injections.' This framing implicitly validates the durability of LLY's existing patient base on Mounjaro and Zepbound.
• Pricing trending down but demand expanding: Bourla noted 'prices going down in the U.S.' but 'Medicare volumes' were a 'positive surprise' — consistent with LLY's own pricing narrative and the July 1 Medicare bridge program catalyst.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: Insider activity since the Q1 earnings date is minimal and not alarming — one small planned sale by an EVP under a 10b5-1 plan and a large institutional sale by Lilly Endowment (a long-standing non-profit shareholder). No open-market discretionary selling by senior management, and no insider buying. The absence of discretionary selling ahead of earnings is a mild positive signal.

Source: SEC Form 4 filings. Open-market buys and sells only (Form 4 codes P/S) plus 10b5-1 plan disclosures. Window: April 30 – August 4, 2026.

No open-market discretionary purchases or sales by C-suite executives (CEO David Ricks, CFO Lucas Montarce) were filed during the period. The Lilly Endowment sale is a routine portfolio management transaction by a long-standing charitable foundation and carries no informational signal about management's view of the business.